Drug Development Consulting Holding ApS - CVR: 42285722

2023, DKK

02.05.2024

Bruttoresultat

-53.330

Primær drift

-53.330

Årets resultat

-9.376'

Aktiver

70.482'

Kortfristede aktiver

270'

Egenkapital

70.460'

Afkastningsgrad

-0 %

Soliditetsgrad

100 %

Likviditetsgrad

+500%

Resultat

02.05.2024

Årsrapport	2023 02.05.2024	2022 16.06.2023	2021 31.05.2022
Nettoomsætning
Bruttoresultat	-53.330	-58.000	40.000
Resultat af primær drift	-53.330	-58.000	40.000
Indtægter af kapitalandele (tilknyttede og associerede)	0	-11.831.000	-15.752.000
Finansielle indtægter	52.000	17.000	0
Finansieringsomkostninger	0	0	0
Andre finansielle omkostninger	0	0	0
Resultat før skat	-9.382.330	-11.872.000	0
Resultat	-9.376.330	-11.874.000	-15.712.000
Forslag til udbytte	0	0	0

Aktiver

02.05.2024

Årsrapport	2023 02.05.2024	2022 16.06.2023	2021 31.05.2022
Kortfristede varebeholdninger	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	6.000	7.000	0
Likvider	264.000	183.000	0
Kortfristede aktiver	270.000	190.000	0
Immaterielle aktiver og goodwill	95.069.900	0	0
Finansielle anlægsaktiver	70.212.000	71.831.000	70.809.000
Materielle aktiver	6.642.820	0	0
Langfristede aktiver	70.212.000	71.831.000	70.809.000
Aktiver	70.482.000	72.021.000	70.809.000

Aktiver

02.05.2024

Passiver

02.05.2024

Årsrapport	2023 02.05.2024	2022 16.06.2023	2021 31.05.2022
Forslag til udbytte	0	0	0
Egenkapital	70.460.370	71.988.000	70.809.000
Hensatte forpligtelser	0	0	0
Langfristet gæld til banker	0	0	0
Anden langfristet gæld	6.181.000	0	0
Leverandører af varer og tjenesteydelser	25.462.000	0	0
Kortfristede forpligtelser	22.000	33.000	0
Gældsforpligtelser	0	0	0
Forpligtelser	0	0	0
Passiver	70.482.000	72.021.000	70.809.000

Passiver

02.05.2024

Nøgletal

02.05.2024

Årsrapport	2023 02.05.2024	2022 16.06.2023	2021 31.05.2022
Afkastningsgrad	-0,1 %	-0,1 %	0,1 %
Dækningsgrad	Na.	Na.	Na.
Resultatgrad	Na.	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.	Na.
Egenkapitals-forretning	-13,3 %	-16,5 %	-22,2 %
Payout-ratio	Na.	Na.	Na.
Gældsdæknings-nøgletal	Na.	Na.	Na.
Soliditestgrad	100,0 %	100,0 %	100,0 %
Likviditetsgrad	1.227,3 %	575,8 %	Na.

Resultat

02.05.2024

Gæld

02.05.2024

Årsrapport

02.05.2024

Nyeste:01.01.2023- 31.12.2023(offentliggjort: 02.05.2024)

Information om virksomhedens regnskabsklasse:The annual report of Drug Development Consulting Holding ApS for 2023 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to reporting class C middle sized entities.

Oplysning om eventualaktiver:Contractual obligations and contingencies, etc. Other contingent liabilitiesThe Company is jointly taxed with its subsidiary Drug Development Consulting BidCo ApS and is jointly and severally liable with other jointly taxed group enterprises for payment of income taxes for the income year 2021 and onwards as well as withholding taxes on interest, royalties and dividends falling due for payment. Other financial obligations20232022Rent and lease liabilities 32. 304,00 22. 959,00 Rent and lease liabilities include rent obligation totalling k. DKK 31. 210, with contract terms within 5 years. the Company has liabilities under operating leases for buildings, cars and IT equipment.

Beretning

02.05.2024

Dato for ledelsens godkendelse af årsrapporten:2024-04-25

Ledelsespåtegning:Ledelsespåtegning

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:Today, the Board of Directors and the Executive Board have discussed and approved the annual report of Drug Development Consulting Holding ApS for the financial year 1 January - 31 December 2023.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:Business reviewDrug Development Consulting Holding ApS was established on 7 April 2021 and on 17 May 2021 Gilde Healthcare, a private equity company with headquarter in the Netherlands, acquired the KLIFO A/S (the KLIFO Group) through subsidiary Drug Development Consulting BidCo ApS. Drug Development Consulting Holding ApS is a shareholder company with no operational activities. KLIFO Group structureKLIFO Group is a drug development consultancy with significant experience in partnering with biotech and pharmaceutical companies to advance their drug development projects. KLIFO offers cross functional consulting and operational solutions spanning all areas of strategic advises, regulatory affairs, CMC development, clinical research, pharmacovigilance, clinical trial supply and quality assurance. Over the past decade, KLIFO has grown to become an established and integrated drug development consultancy providing end to end expert capabilities, enabling our partners to maximize opportunity, mitigate risks, drive innovation and achieve efficient project advancement. In 2023, the biotech market, particularly in the Nordics, faced significant challenges exacerbated by a constrained funding environment post-COVID, coupled with heightened interest and market volatility. These factors notably affected KLIFO during the first half of 2023, resulting in a decline in activity level compared to 2022. To adapt to the new market situation, KLIFO made organizational adjustments throughout 2023. Looking forward, KLIFO is witnessing a rise in activity levels and order book, projecting a return to business growth in 2024.